- Home
- XPON vs ADXN Comparison
XPON vs ADXN Comparison
Compare XPON & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- ADXN
- Stock Information
- Founded
- XPON 2016
- ADXN 2002
- Country
- XPON United States
- ADXN Switzerland
- Employees
- XPON N/A
- ADXN N/A
- Industry
- XPON Electronic Components
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- ADXN Health Care
- Exchange
- XPON Nasdaq
- ADXN Nasdaq
- Market Cap
- XPON 1.8M
- ADXN 11.3M
- IPO Year
- XPON 2022
- ADXN N/A
- Fundamental
- Price
- XPON $3.27
- ADXN $11.26
- Analyst Decision
- XPON
- ADXN Strong Buy
- Analyst Count
- XPON 0
- ADXN 1
- Target Price
- XPON N/A
- ADXN $30.00
- AVG Volume (30 Days)
- XPON 3.1M
- ADXN 24.7K
- Earning Date
- XPON 11-07-2024
- ADXN 11-11-2024
- Dividend Yield
- XPON N/A
- ADXN N/A
- EPS Growth
- XPON N/A
- ADXN N/A
- EPS
- XPON N/A
- ADXN 0.05
- Revenue
- XPON $4,998,801.00
- ADXN $960,641.00
- Revenue This Year
- XPON $0.68
- ADXN N/A
- Revenue Next Year
- XPON $29.04
- ADXN N/A
- P/E Ratio
- XPON N/A
- ADXN $1.87
- Revenue Growth
- XPON N/A
- ADXN N/A
- 52 Week Low
- XPON $2.09
- ADXN $5.00
- 52 Week High
- XPON $639.00
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- XPON 37.66
- ADXN 64.36
- Support Level
- XPON $2.70
- ADXN $10.04
- Resistance Level
- XPON $4.29
- ADXN $10.81
- Average True Range (ATR)
- XPON 0.77
- ADXN 0.63
- MACD
- XPON 0.50
- ADXN 0.08
- Stochastic Oscillator
- XPON 33.62
- ADXN 86.17
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.